2350. Parainfluenza Virus Infection Factors: 18 Years’ Active Surveillance in a Pediatric Hospital
Session: Poster Abstract Session: Pediatric Viral Infections
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • Poster 2350 IDweek 2018.pdf (1.2 MB)
  • Background: Paranfluenza Virus (PIV) is an important cause of acute lower respiratory tract infection (ALRI), hospitalization and mortality in children. The aims of this study were to describe the clinical-epidemiologic pattern and infection factors associated with PIV.

    Methods: Prospective, cross-sectional study of patients admitted for ALRI 2000–2017, diagnosed with respiratory syncytial virus, adenovirus, influenza or parainfluenza by fluorescent antibody (FA) or real-time polymerase chain reaction (RT-PCR) assay of nasopharyngeal aspirates.

    Results: From a total of 15,451 patients included, 13,033 were tested and 45%(5831) had positive samples; RSV was predominant (81.3%,4738) all through the study period, followed by IF:7.6% (440), PIF 6.9%(402) and AV:4.3%(251). PIV followed a seasonal epidemic pattern predominantly during spring months (September- October).

    The median age of cases was 8 months (IQR: 4-13 months); 54% of cases were males. The most frequent clinical presentation was bronchiolitis (61%); 53% had previous admissions for respiratory causes, 9% were readmissions. Comorbidity was found in 59.4%: recurrent respiratory disease (47.8%), congenital heart disease (5.7%), chronic neurological disease (6.5%); 8.5% were malnourished, 23% born preterm and 3.3% immunosuppressed; 23.5% had complications, 10.6% hospital acquired infections. Lethality was 3.5% (14/396).

    The following were independent predictors for PIF infection: recurrent respiratory disease odds ratio (OR): 1.65 (95% CI: 1.32-2.08); p<0.001; readmissions, OR 1.95 (95% CI: 1.34-2.83); p<0.001; born preterm, OR: 1.58 (95% CI: 1.19-2.10); p=0.001.

    Conclusion: Parainfluenza infection showed an epidemic seasonal pattern (September-October), with higher risk in children with recurrent respiratory disease, prematurity and previous admissions for respiratory causes.

    Angela Gentile, MD1, Maria Del Valle Juarez, MD2, Maria Soledad Areso, MD3, Solana Rapaport, MD4, Julia Bakir, MD3, Mariana Viegas, Biochemistry5, Alicia Mistchenko, MD6 and Maria Florencia Lucion, MD7, (1)Epidemiology, Epidemiology Department, "Ricardo Gutierrez"Children's Hospital, Buenos Aires, Argentina, (2)Epidemiology, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina, (3)Epidemiology, "Ricardo Gutiérrez" Children’s Hospital, Buenos Aires, Argentina, (4)"Ricardo Gutiérrez" Children’s Hospital, Buenos Aires, Argentina, (5)Virology, "Ricardo Gutiérrez" Children’s Hospital, Buenos Aires, Argentina, (6)Virology, "Ricardo Gutierrez" Children's Hospital, Buenos Aires, Argentina, (7)Epidemiology, "Ricardo Gutierrez" Children's Hospital, Buenos Aires, Argentina

    Disclosures:

    A. Gentile, Sanofi Pasteur: Consultant , Speaker honorarium .

    M. D. V. Juarez, None

    M. S. Areso, None

    S. Rapaport, None

    J. Bakir, None

    M. Viegas, None

    A. Mistchenko, None

    M. F. Lucion, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.